(1S,2R)-(+)-Norephedrine structure
|
Common Name | (1S,2R)-(+)-Norephedrine | ||
---|---|---|---|---|
CAS Number | 37577-28-9 | Molecular Weight | 187.667 | |
Density | 1.071g/cm3 | Boiling Point | 288.1ºC at 760mmHg | |
Molecular Formula | C9H13NO | Melting Point | 51-54ºC | |
MSDS | USA | Flash Point | 235.4 °F | |
Symbol |
GHS07 |
Signal Word | Warning |
Name | (1S,2R)-(+)-Norephedrine |
---|---|
Synonym | More Synonyms |
Density | 1.071g/cm3 |
---|---|
Boiling Point | 288.1ºC at 760mmHg |
Melting Point | 51-54ºC |
Molecular Formula | C9H13NO |
Molecular Weight | 187.667 |
Exact Mass | 187.076385 |
PSA | 46.25000 |
LogP | 1.76750 |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R22;R36/37/38 |
Safety Phrases | S26 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 2922199090 |
Flash Point(F) | 235.4 °F |
Flash Point(C) | 113 °C |
Precursor 7 | |
---|---|
DownStream 7 | |
HS Code | 2922199090 |
---|---|
Summary | 2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.
J. Clin. Psychopharmacol. 35 , 694-9, (2015) The use of khat (Catha edulis) while on medication may alter treatment outcome. In particular, the influence of khat on the metabolic activities of drug-metabolizing enzymes is not known. We performed... |
|
Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.
Pharm. Res. 32(5) , 1519-45, (2015) Lipid excipients are applied for numerous purposes such as taste masking, controlled release, improvement of swallowability and moisture protection. Several melting techniques have evolved in the last... |
|
The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.
Pharmacoeconomics 33 , 749-63, (2015) Following withdrawals, failures, and significant litigation settlements, drug product launches in the anti-obesity category slowed despite a large and growing unmet need. Litigation concerns, a more r... |
EINECS 238-900-2 |
dl-phenylpropanolamine |
d-NOREPHEDRINE BASE |
(1R,2S)-2-Amino-1-phenyl-1-propanol hydrochloride (1:1) |
PHENYLPROPANOLAMINEBASE |
d-Phenylpropanolamine |
dl-NOREPHEDRINE BASE |
MFCD00064411 |
Benzenemethanol, α-[(1S)-1-aminoethyl]-, (αR)-, hydrochloride (1:1) |
dl-propadrine |